During the corresponding time, Merus N V recorded a revenue increase by 3.21 % year on year, sequentially revenue grew by 37.63 %. While revenue at the Merus N V 's corporate clients
Immunotherapy Advances: SYNC-T for Prostate Cancer and Merus for Head and Neck Cancer In recent developments in cancer therapeutics, innovative immunotherapy treatments have shown promising efficacy, highlighting a transformative era in managing metastatic cancers. Notably, Syncromune Inc. announced at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 that their SYNC-T therapy has demonstrated an impressive overall response rate of 87% in patients suffering from metastatic prostate cancer, signifying a substantial step forward in personalized cancer treatment. SYNC-T Therapy for Metastatic Prostate CancerSYNC-T therapy is characterized as a first-in-class in situ personalized immunotherap...
Merus N.V. a clinical-stage immuno-oncology company, has released interim data showcasing the efficacy of its novel antibody, Petosemtamab, in second-line or later (2L+) recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). This data indicates clinically meaningful activity in this challenging-to-treat cancer population. Concurrently, the company reported a significant increase in revenue, reflecting both the potential market success of Petosemtamab and its strategic growth. Petosemtamab Monotherapy in 2L+ r/m HNSCCPetosemtamab is a unique bispecific antibody that targets both EGFR (epidermal growth factor receptor) and LGR5 (leucine-rich repeat-containing G-protein coupled receptor 5), tw...
Merus N.V., a clinical-stage oncology company specializing in multispecific antibodies, showcased promising single-agent efficacy results for its investigational therapy MCLA-129 targeting MET exon 14 (METex14) non-small cell lung cancer (NSCLC) during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation occurred against a backdrop of significant financial growth for the company. Merus N.V. (Nasdaq: MRUS) presented exciting preclinical and clinical data at the prestigious ASCO Annual Meeting, which was held from May 31 to June 4, 2024. MCLA-129, a multispecific antibody, showed potential as a single-agent therapy for patients with METex14 NSCLC, drawing consider...
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg Being Investigated in Macrophage Activation SyndromeIn an exciting development for the field of rare diseases, biopharmaceutical company Sobi has recently announced that the US Food and Drug Administration (FDA) has granted fast track designation to their drug candidate, emapalumab-lzsg. This drug is being investigated as a potential first therapeutic option for patients diagnosed with Macrophage Activation Syndrome (MAS), a life-threatening hyperinflammatory condition. Sobi s fast track designation is a significant step forward in bringing this potentially life-saving treatment to individuals suffering from MAS.MAS is a complication often assoc...
In recent studies, Merus N.V., a biopharmaceutical company, announced the acceptance and priority review by the U.S. Food and Drug Administration (FDA) of their biologics license application for Zeno. Zeno is a potential targeted therapy indicated for the treatment of NRG1+ non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). If approved, Zeno will represent a major breakthrough as the first targeted therapy for NRG1+ cancer.Background:NRG1 (Neuregulin 1) gene fusions have been identified as a driver mutation in several cancer types, including NSCLC and PDAC. These gene fusions result in the overexpression of NRG1 protein, which leads to uncontrolled cell proliferation and tumor gr...
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., April 08, 2024 - Merus N.V. (Nasdaq: MRUS), an innovative player in the landscape of clinical-stage oncology, has disclosed intriguing preclinical data revolving around its promising candidate, zenocutuzumab (Zeno). The revelations, made at the renowned American Association of Cancer Research (AACR) Annual Meeting 2024, pointed to the effectiveness of Zeno in cancer models with high Neuregulin 1 (NRG1) expressions.Merus, recognized for its commitment to developing groundbreaking, full-length multispecific antibodies, specifically Biclonics® and Triclonics®, has been focused on leveraging the potential of Zeno. This drug s efficacy against cancer types associa...
Merus N.V., a leading clinical-stage immuno-oncology company, recently presented encouraging interim data on its immunotherapy drug MCLA-129 at the prestigious ESMO Asia Congress 2023. The company also reported a remarkable revenue increase during the same period. This article delves into the details of Merus N.V. s potential breakthrough in treating EGFRm NSCLC and explores its financial success. Expanding Treatment Options for EGFRm NSCLC: Merus N.V. is set to launch a groundbreaking clinical trial to evaluate the combination of MCLA-129 with chemotherapy in patients with 2L+ EGFRm NSCLC. This innovative treatment approach is scheduled to commence in the first quarter of 2024. The company...
Sources:
Merus N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Merus N v’s corporate clients.
For your research, we’ve provided 9 tables on Merus N v corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %